W 1 - Heart



Contraindications to MRI (ht125039)

T Dill

Web only references

1. Schenck JF. Health effects and safety of static magnetic fields. In: Shellock FG, ed. Magnetic resonance procedures: health effects and safety. Boca Raton, Fla: CRC, 2001:1–30.

2. Zaremba LA. FDA guidance for magnetic resonance system safety and patient exposures: current status and future considerations. In: Shellock FG, ed. Magnetic resonance procedures: health effects and safety. Boca Raton, Fla: CRC, 2001:183–196.

3. Sawyer-Glover AM, Shellock FG. Pre-MRI procedure screening: recommendations and safety considerations for biomedical implants and devices. J Magn Reson Imaging 2000;12:510.

4. Evans JC, Smith ET, Nixon TE. A national survey of attitudes towards the use of MRI in patients known to have intracranial aneurysm clips. Brit J Radiol 2001;74:1118–1120.

5. Lee Pride G, Kowal J, Mendelsohn DB, et al. Safety of MR scanning in patients with nonferromagnetic aneurysm clips. J Magn Reson Imaging 2000;12:198–200.

6. Williamson MR, Espinosa MC, Boutin RD, et al. Metallic foreign bodies in the orbits of patients undergoing MR imaging: prevalence and value of radiography and CT before MR. Am J Roentgenol 1994;162:981–983.

7. Gieszl R, Williams KD, Drayer BP, et al. Magnetic resonance imaging and ferromagnetic bullets. Assoc Firearm and Tool Mark Examiners 1989;J21:595–604.

8. Teitelbaum GP, Yee CA, Van Horn DD, et al. Metallic ballistic fragments: MR imaging safety and artefacts. Radiology 1990;175:855–859.

9. American Society for Testing and Materials (ASTM) Designation F 2052. Standard test method for measurement of magnetically induced displacement force on passive implants in the magnetic resonance environment. In: Annual Book of ASTM Standards, Section 13, Medical Devices and Services, 01 Medical Devices; Emergency Medical Services. West Conshohocken, PA, 2002;13:1576–1580.

10. Syed MA, Carlson K, Murphy M, et al. Long-term safety of cardiac magnetic resonance imaging performed in the first few days after bare-metal stent implantation. J Magn Reson Imaging 2006;24:1056–1061.

11. Shellock FG, Forder JR. Drug eluting coronary stent: in vitro evaluation of magnetic resonance safety at 3 Tesla. J Cardiovasc Magn Reson 2005;7:415–419.

12. Shellock FG, Morisoli SM. Ex vivo evaluation of ferromagnetism, heating, and artifacts produced by heart valve prostheses exposed to a 1.5-T MR system. J Magn Reson Imaging 1994;4:756–758.

13. Shellock FG, Morisoli SM. Ex vivo evaluation of ferromagnetism and artifacts of cardiac occluders exposed to a 1.5-T MR system. J Magn Reson Imaging 1994;4:213–215.

14. Dempsey MF, Condon B, Hadley DM. Investigation of the factors responsible for burns during MRI. J Magn Reson Imaging 2001;13:627–631.

15. Kalin R, Stanton MS. Current clinical issues for MR scanning of pacemaker and defibrillator patients. Pacing Clin Electrophysiol 2005;28:326–8.

16. Stanton MS. Industry viewpoint: Medtronic: Pacemakers, ICDs, and MRI. Pacing Clin Electrophysiol 2005;28:265.

17. Levine PA. Industry viewpoint: St. Jude Medical: Pacemakers, ICDs and MRI. Pacing Clin Electrophysiol 2005;28:266–7.

18. Faris OP, Shein MJ. Government viewpoint: U.S. Food & Drug Administration: Pacemakers, ICDs and MRI. Pacing Clin Electrophysiol 2005;28:268–9.

19. Martin ET, Coman JA, Shellock FG, et al. Magnetic resonance imaging and cardiac pacemaker safety at 1.5-Tesla. J Am Coll Cardiol 2004;43:1315–24.

20. Gimbel JR, Kanal E, Schwartz KM, et al. Outcome of magnetic resonance imaging (MRI) in selected patients with implantable cardioverter defibrillators (ICDs). Pacing Clin Electrophysiol 2005;28:270–3.

21. Nahrendorf M, Hiller KH, Hu K, et al. Pacing in high field cardiac magnetic resonance imaging. Pacing Clin Electrophysiol 2004;27:671–74.

22. Duru F, Luechinger R, Scheidegger MB, et al. Pacing in magnetic resonance imaging environment: clinical and technical considerations on compatibility. Eur Heart J 2001;22:113–124.

23. Hartnell GG, Spence L, Hughes LA, et al. Safety of MR imaging in patients who have retained metallic materials after cardiac surgery. Am J Roentgenol 1997;168:1157–1159.

24. Hess T, Stepanow B, Knopp MV. Safety of intrauterine contraceptive device during MR imaging. Eur Radiol 1996;6:66–68.

25. Teissl C, Kremser C, Hochmair ES, et al. Magnetic resonance imaging and cochlear implants: compatibility and safety aspects. Journal of Magnetic Resonance Imaging 1999;9:26–38.

26. Vahlensieck M. Tattoo-related cutaneous inflammation (burn grade I) in a mid-field MR scanner [Letter]. Eur Radiol 2000;10:97.

27. Colletti PM. Magnetic resonance procedures and pregnancy. In: Shellock FG, ed. Magnetic resonance procedures: health effects and safety. Boca Raton, Fla: CRC, 2001:149–182.

28. Shellock FG, Kanal E. Policies, guidelines, and recommendations for MR imaging safety and patient management. J Magn Reson Imaging 1991;1:97–101.

29. Rofsky NM, Pizzarello DJ, Weinreb JC, et al. Effect on fetal mouse development of exposure to MR imaging and gadopentate dimeglumine. J Magn Reson Imaging 1994;4:805–807.

30. Soltys RA. Summary of preclinical safety evaluation of gadoteridol injection. Invest Radiol 1992;27(suppl 1):S7–S11.

31. Kanal E, Borgstede JP, Barkovich AJ, et al. American College of Radiology White Paper on MR Safety: 2004 update and revisions. Am J Roentgenol 2004;182:1111–1114.

32. Morsetti A, Bussi S, Tirone P, et al. Toxicological safety evaluation of gadobenate dimeglumine 0,5 M solution for injection (Multihance), a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 1999;23(suppl 1):S207–S217.

33. Kubik-Huch RA, Gottstein-Aalame NM, Frenzel T, et al. Excretion of gadopentetate dimeglumine into human breast milk during lactation. Radiology 2000;216:555–558.

34. Saenz A, Mandal R, Kradin R, et al. Nephrogenic fibrosing dermopathy with involvement of the dura mater. Virchows Arch 2006;449:389–391.

35. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta 1 expression in affected skin. Arthritis Rheum 2004;50:2660–2666.

36. Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 2004;30:569–577.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download